2 results
Approved WMOWill not start
The primary objectives of this study are to establish the efficacy and safety of APL-2 compared to eculizumab in patients with PNH who continue to have Hb levels <10.5 g/dL despite treatment with eculizumab.
Approved WMOPending
Primary objective: to investigate whether HPA-axis responses during the ACTH (Synacthen) stimulation are differentially influenced by distinct hormonal contraceptives, as compared to responses measured during the natural menstrual cycle (luteal…